Personal profile
Research interests
Metal chelators as therapeutic compounds, in particular in cancer, neurodegenerative diseases and as biostatic agents against microorganisms.
We focus on the design of powerful Fe(III) chelators of the hydroxypyridinone family that have been demonstrated by us and others to have activity as:
anticancer drugs, interfering with the biochemical processes involving metals (metalloenzymes, oxidative stress)
drugs against neurodegenerative diseases, preventing oxidative damage to neurons
biostatic agents, reducing the rate of growth of microorganisms.
Biography
I am an organic chemist who is designing novel powerful metal chelators, with a focus on Fe(III) that can have therapeutic applications, in particular against cancer, neurodegenerative diseases (Parkinson's Disease, Alzheimer's Disease) and as biostatic agents against micro-organisms. My molecules are based on rationale design, trying to optimise metal chelator and other functions such as cell penetration, multiple mode of action, targeting.
Education/Academic qualification
Teaching & Learning, PCAPL
11 Oct 2007 → 10 Oct 2008
Award Date: 10 Oct 2008
Chemistry, PhD
1 Sept 1993 → 30 Oct 1996
Award Date: 30 Oct 1996
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines
Abdelaal, G., Carter, A., Cheung, W., Panayiotidis, M. I., Racey, S., Tétard, D. & Veuger, S., 24 Jul 2023, In: Biomedicines. 11, 7, 2073.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus)44 Downloads (Pure) -
1-Hydroxy-2(1H)-pyridinone-Based Chelators with Potential Catechol O-Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson’s Disease
Bergin, J. C. J., Tan, K. K., Nelson, A. K., Amarandei, C.-A., Hubscher-Bruder, V., Brandel, J., Voinarovska, V., Dejaegere, A., Stote, R. H. & Tetard, D., 28 Apr 2022, In: Molecules. 27, 9, 20 p., 2816.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus)56 Downloads (Pure) -
Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines
Abdelaal, G., Carter, A., Panagiotidis, M., Tetard, D. & Veuger, S., 23 Sept 2022, In: Frontiers in Molecular Biosciences. 9, 13 p., 1005092.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Citations (Scopus)31 Downloads (Pure) -
Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1H)-one iron chelators in an in vitro cell model of Parkinson's disease
Lewis, F. W., Bird, K., Navarro, J.-P., El Fallah, R., Brandel, J., Hubscher-Bruder, V., Tsatsanis, A., Duce, J. A., Tetard, D., Bourne, S., Maina, M. & Pienaar, I. S., 1 Mar 2022, In: Dalton Transactions. 51, 9, p. 3590-3603 14 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Citations (Scopus)130 Downloads (Pure) -
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma
Kyriakou, S., Cheung, W., Mantso, T., Mitsiogianni, M., Anestopoulos, I., Veuger, S., Trafalis, D. T., Franco, R., Pappa, A., Tetard, D. & Panayiotidis, M. I., 1 Aug 2021, In: Investigational New Drugs. 39, 4, p. 971-986 16 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile7 Citations (Scopus)214 Downloads (Pure)